Indobufene Eg

Indobufen, the active ingredient in Indobufene Eg, is an antiplatelet agent presented as an oral tablet for oral use. It is employed to prevent arterial thrombosis, to provide secondary prevention after myocardial infarction, and to reduce the risk of stroke in patients with atherosclerotic disease.

GNH USA supplies Indobufene Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indobufen acts on platelet aggregation pathways to lower the risk of thrombotic events. - Arterial thrombosis: reduces formation of clots within arteries, helping maintain blood flow. - Secondary myocardial infarction: lowers the chance of recurrent heart attacks after an initial event. - Ischemic stroke in atherosclerotic disease: helps prevent stroke episodes by inhibiting platelet‑driven clot formation.

Indobufen is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Gastrointestinal discomfort: mild stomach upset or irritation. - Nausea: feeling of queasiness that may lead to vomiting. - Dyspepsia: indigestion or heartburn. - Headache: mild to moderate pain in the head region. - Dizziness: transient light‑headedness. - Diarrhoea: loose stools occurring occasionally.

Serious or Rare Side Effects: - Severe bleeding: unexpected or prolonged hemorrhage, including gastrointestinal or intracranial bleeding. - Hypersensitivity reactions: rash, itching, or swelling that may indicate an allergic response. - Liver enzyme elevation: abnormal liver function tests suggesting hepatic involvement. - Thrombocytopenia: reduced platelet count that can increase bleeding risk. - Anaphylaxis: rare, life‑threatening allergic reaction requiring immediate medical attention.

Before initiating therapy with Indobufen, clinicians should consider several safety measures. - Assess bleeding risk: evaluate patient history for ulcers, recent surgery, or coagulopathy. - Monitor liver function: periodic liver enzyme tests are advisable. - Avoid in active peptic ulcer disease: the drug may exacerbate gastrointestinal lesions. - Use caution in renal impairment: dose adjustment may be needed. - Do not combine with other antiplatelet agents without supervision: increased bleeding potential. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Indobufen may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Warfarin: additive anticoagulant effect can markedly increase bleeding risk. - Heparin: combined use may lead to excessive anticoagulation and hemorrhage.

Moderate Interactions (Monitor Closely): - NSAIDs: concurrent use may heighten gastrointestinal bleeding. - SSRIs (selective serotonin reuptake inhibitors): may increase bleeding tendency. - ACE inhibitors: monitor blood pressure as combined therapy can affect hemodynamics.